BioSyent Inc. (TSXV:RX)

Market Cap	136.72M
Revenue (ttm)	42.18M
Net Income (ttm)	8.63M
Shares Out	11.26M
EPS (ttm)	0.75
PE Ratio	16.25
Forward PE	14.28
Dividend	0.20 (1.65%)
Ex-Dividend Date	Nov 28, 2025

Volume	510
Average Volume	4,905
Open	12.17
Previous Close	12.14
Day's Range	11.95 - 12.17
52-Week Range	9.20 - 12.49
Beta	0.39
RSI	67.35
Earnings Date	Nov 20, 2025

About BioSyent

BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Country: Canada
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: RX

Financial Performance

In 2024, BioSyent's revenue was 35.03 million, an increase of 10.89% compared to the previous year's 31.59 million. Earnings were 7.27 million, an increase of 12.54%.